Vanguard Personalized Indexing Management LLC Grows Position in Chemed Corporation $CHE

Vanguard Personalized Indexing Management LLC grew its stake in shares of Chemed Corporation (NYSE:CHEFree Report) by 8.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,760 shares of the company’s stock after buying an additional 136 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Chemed were worth $857,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Renasant Bank increased its position in Chemed by 2.3% during the first quarter. Renasant Bank now owns 815 shares of the company’s stock worth $501,000 after buying an additional 18 shares in the last quarter. Cim LLC grew its position in shares of Chemed by 1.0% in the first quarter. Cim LLC now owns 2,029 shares of the company’s stock valued at $1,248,000 after purchasing an additional 21 shares during the period. First Horizon Advisors Inc. grew its position in shares of Chemed by 16.1% in the first quarter. First Horizon Advisors Inc. now owns 173 shares of the company’s stock valued at $107,000 after purchasing an additional 24 shares during the period. Cynosure Group LLC grew its position in shares of Chemed by 4.3% in the first quarter. Cynosure Group LLC now owns 581 shares of the company’s stock valued at $358,000 after purchasing an additional 24 shares during the period. Finally, Farther Finance Advisors LLC grew its position in shares of Chemed by 23.0% in the first quarter. Farther Finance Advisors LLC now owns 150 shares of the company’s stock valued at $93,000 after purchasing an additional 28 shares during the period. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Analysts Set New Price Targets

CHE has been the subject of a number of recent analyst reports. Bank of America lowered their price objective on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research report on Wednesday, September 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Oppenheimer lowered their price objective on Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research report on Thursday, July 31st. Royal Bank Of Canada lowered their price objective on Chemed from $640.00 to $589.00 and set an “outperform” rating for the company in a research report on Thursday, July 31st. Finally, Wall Street Zen downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Saturday, July 5th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $578.50.

Get Our Latest Research Report on Chemed

Insider Buying and Selling

In other Chemed news, EVP Nicholas Michael Westfall sold 10,012 shares of the business’s stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $421.91, for a total transaction of $4,224,162.92. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director George J. Walsh III acquired 200 shares of Chemed stock in a transaction on Monday, August 4th. The shares were bought at an average price of $417.10 per share, for a total transaction of $83,420.00. Following the purchase, the director owned 3,523 shares of the company’s stock, valued at $1,469,443.30. This represents a 6.02% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 13,162 shares of company stock worth $5,677,511. Company insiders own 3.29% of the company’s stock.

Chemed Trading Up 2.1%

Shares of Chemed stock opened at $440.10 on Monday. Chemed Corporation has a twelve month low of $408.42 and a twelve month high of $623.60. The stock has a market capitalization of $6.41 billion, a P/E ratio of 22.63, a PEG ratio of 2.56 and a beta of 0.43. The business’s fifty day moving average price is $448.87 and its 200 day moving average price is $502.85.

Chemed (NYSE:CHEGet Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.02 by ($1.75). Chemed had a net margin of 11.56% and a return on equity of 25.83%. The firm had revenue of $618.80 million during the quarter, compared to analyst estimates of $650.60 million. During the same quarter in the previous year, the business posted $5.47 EPS. Chemed’s revenue was up 3.8% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, sell-side analysts predict that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 11th were paid a dividend of $0.60 per share. This is a boost from Chemed’s previous quarterly dividend of $0.50. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Monday, August 11th. Chemed’s payout ratio is presently 12.34%.

Chemed Company Profile

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Recommended Stories

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHEFree Report).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.